YD Bio Limited Ordinary Shares (YDES) is a publicly traded the market company. As of May 21, 2026, YDES trades at $4.55 with a market cap of $358.41M and a P/E ratio of 0.00. YDES moved +0.00% today. Year to date, YDES is -64.12%; over the trailing twelve months it is flat. Its 52-week range spans $4.37 to $25.00. Rallies surfaces YDES's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
YD Bio Reports 17% Revenue Growth to $596.8M, Net Loss Widens to $8.3M: YD Bio completed its merger with Breeze Holdings in August 2025 and secured $13.2M in PIPE financing, ending 2025 with $6.0M in cash. Full-year net revenue rose 17% to $596.8M driven by pharmaceutical sales, while net loss widened to $8.31M as operating expenses jumped 226%.
| Metric | Value |
|---|---|
| Price | $4.55 |
| Market Cap | $358.41M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.00 |
| 52-Week Low | $4.37 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
YDES analyst coverage data. Average price target: $0.00.